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The intravenous route remains the preferred route for anticancer therapy. A less ex-
plored, albeit useful, portal for administration is into the peritoneal cavity via intraperi-
toneal injection. The fundamental goal of intraperitoneal administration of antineoplas-
tic agents is to increase the exposure of cancer cells within the peritoneal cavity to the
drug while minimizing potential toxic effects on internal organs. This may provide sig-
nificant advantages in the treatment of cancers of peritoneal organs. 5-FU is an anti-neo-
plastic drug used in the palliative treatment of cancers of the ovary, gastrointestinal
tract, breast, respiratory tract, etc. (1). 5-FU has high activity in the treatment of drug re-
sistant colon cancer. It has been most widely used for the treatment of breast cancers,
ovarian cancer and it is also used in combination with other anti-cancer drugs like leu-
covorin (2). A number of marketed injectable formulations of 5-FU are available as solu-
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tions for intravenous administration and as topical creams and ointments for the treat-
ment of actinic keratoses (3).
The antineoplastic activity of 5-FU is exerted by blocking the methylation reaction
of deoxyuridylic acid to thymidylic acid leading to thymine deficiency and consecuti-
vely interference with the synthesis of DNA and, to a lesser extent, inhibition of the for-
mation of RNA, unbalanced growth and death of the cell. The effects of DNA and RNA
deprivation are most marked on those cells which grow more rapidly and which take up
5-FU at a more rapid rate. Hence, intravenous antineoplastic therapy using 5-FU is asso-
ciated with several adverse effects on cardiac, hematologic, neurological and gastroin-
testinal systems (4). Intraperitoneal 5-FU chemotherapy is reported to increase exposure
to higher drug concentrations for a longer period of time in tumors of the peritoneal cav-
ity while reducing systemic effects. Improved cytotoxicity is attributed to free diffusion
of the drug from the peritoneal surface into the tumor (5). This is of special relevance
since 5-FU is widely used for the treatment of cancers of organs in the peritoneal cavity,
including abdominal and ovarian cancers.
Chitosan is the deacetylated derivative of chitin, a natural component of shrimp
and crab shells. It is a biocompatible, cationic polymer, soluble in aqueous media at pH
< 6.2 (depending upon the degree of deacetylation) (6). Basification of chitosan solutions
above this pH leads to precipitation. pH-gelling, cationic chitosan solutions can be trans-
formed into thermally sensitive, pH-dependent, gel-forming systems by the addition of
polyol salts such as glycerolphosphate (GP) (6, 7). GP is an organic compound naturally
found in the body, which is usually used as a source of phosphate in the treatment of im-
balance of phosphate metabolism. Its venal administration has been approved by FDA
(8). In the present study, GP represents the disodium salt of b-glycerophosphate. Chito-
san-glycerolphosphate (C-GP) systems possess a neutral pH, remain liquid at or below
room temperature, and form monolithic gels at body temperature (9). Hence, they offer a
unique advantage in drug therapy in that they are injectable fluids at room temperature
and would be converted in vivo to compact depots for prolonged drug release.
The present project was aimed at formulation of a chitosan based thermoreversible
gel for intraperitoneal administration of 5-FU. We hypothesized that the formulation
would gel post injection and provide high local concentrations of 5-FU in a sustained
manner, thereby increasing efficacy, reducing systemic toxicity and offering the possibi-
lity of reducing frequent drug administration. The gel was evaluated for in vitro toxicity
in mouse L-929 fibroblasts and for in vivo toxicity and efficacy in suitable mice strains.
EXPERIMENTAL
Materials
Chitosan (degree of deactylation ~89 % and molecular weight ~73000 Da) was sup-
plied by the Central Institute of Fishery Technology, Cochin, India. GP was purchased
from the Central Drug House, Delhi, India. 5-FU was a gift from Naprod Life Sciences
Ltd. Mumbai, India. Dulbecco’s Modified Eagle’s Medium (DMEM) was procured from
Himedia, Mumbai, India, Foetal calf serum, 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyl te-
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trazolium bromide (MTT), dimethyl sulfoxide (DMSO) and trypsin were purchased from
Sigma-Aldrich, USA. L-929 mouse fibroblast cells were procured from NCCS, Pune, In-
dia.
Preparation of sterile chitosan-GP-5-FU (C-GP-5FU) gels
Sterile formulations were prepared by aseptic processing of presterilized compo-
nents. 5-FU was sterilized by g-radiation (2.5 Mrad) at BRIT, Mumbai, India. A solution
of chitosan (0.1 g) in 0.1 mol L–1 HCl (4 mL) was subjected to autoclaving at 121 °C for 15
min at 103.4 kPa. To the sterilized chitosan solution, presterilized 5-FU (62.5 mg) was ad-
ded under a laminar flow hood and dissolved. GP was weighed, dissolved in distilled
water, and sterilized by passage through a 0.22 mm membrane syringe filter (Millipore)
under the laminar flow hood to make 50 % (m/V) GP solutions. Both chitosan and GP so-
lutions were cooled to 15 °C. 1 mL of GP solution was added dropwise into the cold
chitosan solution under aseptic conditions with continuous mixing using a cyclomixer.
The above procedure resulted in the preparation of a C–GP-5FU system containing
2 % (m/V) chitosan, 10 % (m/V) GP and 12.5 mg mL–1 5-FU. Drug free mixtures were pre-
pared in a similar manner, except that addition of 5-FU into the chitosan solution was
omitted.
Evaluation of C-GP-5FU gel
Gelation temperature, time and pH (10). – The gelling temperature was measured by
immersing the test tubes containing sols in a thermostated water bath and increasing the
temperature gradually from 15 to 40 °C at a rate of 0.5 °C min–1. The temperature was
maintained stable for 10 min at 15, 25, 37 and 40 °C. The tubes were inverted at frequent
intervals until movement of the meniscus of the sol on tilting of the tube was arrested.
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Fig. 1. Appearance of gel at different tempe-
ratures a) 15, b) 25, c) 37, d) 40 °C.
Gelation time was measured as the time required to stop the flow of gel at 37 °C on im-
mersing the solutions in a thermostatic water bath. Pictures of sol-to-gel transformation
were recorded with the help of a digital camera. pH of the gel was recorded at room
temperature using a standardized pH meter.
In vitro drug release. – In vitro drug release from the formulation gelled at 37 °C was
determined in duplicates using a USP dissolution apparatus 4 – flow through cell (Sotax
CE-1 with cell 3252). A ruby bead was placed in the lower half of the cell, followed by
loading of glass beads 1 mm in diameter (1 g) into the release compartment of the appa-
ratus. The upper half of the cell with a capacity of 5 mL was fitted on the lower one.
C-GP-5FU gel (1 g) was then gently placed over the glass beads. Stainless steel sieves
were placed above the upper half of the cell, followed by a 0.2-mm membrane filter. The
whole assembly was covered by the adapter containing output tubing, placed in a water
bath maintained at 37 °C and allowed to equilibrate for 15 min prior to commencing the
flow of the release medium (Fig. 2).
In operation, the release medium (distilled water) was pumped at a rate of 10 mL
h–1 and was delivered past the sample in the cell. Fresh medium was continuously pum-
ped and the eluate was collected after 0.5, 1, 2, 3, 4, 5, 6, 8, 10 and 12 h. The medium from
the system was collected as the entire outflow over the sampling interval. Aliquots were
diluted appropriately and the 5-FU released over a period of 12 h was quantified by UV
spectrophotometric measurement at 266 nm. Release profile was plotted as cumulative
percent released vs. time.
In vitro cell line cytotoxicity studies
L-929 mouse fibroblast cells were used to assess the cytotoxicity of drug free C–GP
systems. Cells were subcultured in DMEM containing 10 % fetal calf serum and main-
tained in a humidified atmosphere (5 % CO2/95 % O2) until they were at least 75–80 %
confluent, with good morphology. 1 mL trypsin was added to disaggregate the cells.
Culture vessels were incubated at 37 °C for two minutes, after which cell detachment
was monitored under the microscope. Once the cells were detached, 1 mL DMEM was
added to dilute the trypsin and to disperse the cells. The cells were transferred to a ster-
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Fig. 2. Flow through a cell containing C-GP-5FU gel.
ile conical centrifuge tube and centrifuged at 900 rpm for 2 min followed by dilution
with culture medium to attain a cell density of 2 x10–5 cells mL–1. Quantification was
achieved using hemocytometry.
A 96-well plate was seeded with 100 mL of the above cell suspension, resulting in
20,000 cells in each well. Six cells were reserved as blank, which contained only 100 mL of
medium. The plates were incubated at 37 °C in a humidified atmosphere (5 % CO2/95 %
O2) for 24 h.
After 24 h, different amounts of sterile drug free C-GP systems per well (10, 25, 50,
100 mL) were added to six wells each. In wells with 10, 25 and 50 mL, of the test formula-
tion, a further corresponding amount of DMEM was added to ensure a total volume of
100 mL before addition of the test formulation. Six wells containing only cells and me-
dium served as the control. At the end of an incubation period of 24 h, the supernatant
medium and test material were removed from all the wells using a fine gauge needle
and replaced with 100 µL of a 2 mg/mL MTT solution in phosphate buffered saline A.
The plates were wrapped in aluminium foil to protect them from light and incubated for
4 h in an atmosphere of 5 % CO2.
At the end of 4 h, the supernatant MTT solution was removed using a fine gauge
needle and 100 µL of DMSO solution was added to dissolve the formazan crystals.
Absorbance was recorded at 540 nm on an ELISA plate reader.
Taking the mean absorbance of the control wells as corresponding to 100 % prolife-
ration, percent proliferation for all the treated wells was estimated. Data was analyzed
for statistical significance using ANOVA and Bonferroni’s multiple comparison tests.
Toxicity studies
Acute toxicity studies: Determination of LD50. – In vivo toxicity of the formulation was
assessed in Swiss albino mice. The studies were approved by the institutional ethics
committee of the Bombay College of Pharmacy, Kalina, Mumbai, India, for animal ex-
periments protocol no. 30/2007. LD50 was determined by the up-and-down method as
described in OECD guidelines (11) using the Statistical Program (AOT425StatPgm).
The animals were fasted for 24 h prior to dosing. C-GP-5FU formulation was ad-
ministered in a single dose by intraperitoneal route with a 22 gauge needle. Each animal
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Table I. Observations of animal mass and mortality during toxicity studies
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was dosed in sequence, usually at 48 h intervals. The first animal was dosed at the best
preliminary estimate of LD50 of 5-FU as found in the literature (100 mg kg–1). The subse-
quent animal received a higher dose (if the earlier animal survived) or a lower dose (if
the earlier animal died) (Table I). Doses administered were as per recommendation of
the AOT425StatPgm software. Animals were observed with special attention during the
first 4 h and frequently thereafter, for a total of 48 h. Masses of animals were recorded at
the time of dosing and every 24 h thereafter. The mortality results of the animals were
continuously fed into the AOT425StatPgm statistical program and the procedure was
terminated after dosing six animals.
In vivo antitumor efficacy testing
The antitumor efficacy of 5-FU in solution and of thermoreversible C-GP-5FU gels
was investigated in subcutaneously grown murine colon tumor model colon-26 in
BALB/c mice. Initially, a donor tumor-bearing BALB/c mouse was sacrificed and the tu-
mor was cut into 2 mm3 pieces. Tumor pieces were transplanted in the dorsal hind limb
area into 18 experimental male BALB/c mice each six to eight weeks of age and weigh-
ing 18–22 g. The animals were housed in autoclaved and secured cages throughout the
study.
The tumor was allowed to grow for a week after which the animals were divided
randomly into three groups, with six mice each. In case of treated animals, a calculated
volume of injection was administered intratumorally using a 22 gauge needle. Each
treated animal received a dose equivalent to 60 mg kg–1 of 5-FU. The first group recei-
ved the test formulation (C-GP-5FU), second group was treated with the commercial for-
mulation (Fivoflu® 250, Dabur 50 mg mL–1) and the third group served as the untreated
control. Animals were dosed starting on day 1 and then after skipping three days for a
total of 17 days (5 injections). Following a schedule similar to that of drug administra-
tion, tumor volume and masses of animals as well as animal mortality were recorded for
a period of 32 days. These measurements were continued for 15 days after the last injec-
tion on day 17.
Tumor volume was measured by Max-cal calipers. The relative tumor volume (RTV)
was expressed as V/V0 index (12, 13) where
V = Tumor volume on the last day of measurement
V0 = Initial volume of the same tumor on the day the measurement was started.
Mortality of the animals was also recorded. The data obtained was analyzed statisti-
cally using one-way ANOVA Bonferroni’s multiple comparison test (p < 0.01).
RESULTS AND DISCUSSION
Preparation and evaluation of gels
Gradual addition of GP solution to chitosan at temperatures lower than 15 °C was
found to be crucial for the preparation of thermoreversible systems. The prepared sols
were found to set into gels at physiological temperature after 8–10 min. The nearly trans-
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parent gels gradually turned opaque with the increase in temperature. Gel appearance at
different temperatures (15, 25, 37 and 40 °C) can be seen in Fig. 1. On inverting, the for-
mulation was flowable at all temperatures tested until physiological temperature was at-
tained. At 37 °C, the sol was found to set into a relatively stiff mass that did not flow
upon tube inversion. The pH of all solutions and gel formulations was found to be al-
most neutral.
Chitosan is a cationic polysaccharide soluble in aqueous media of pH < 6.2. In the
absence of GP, repulsion between the positively charged chitosan chains did not allow
any interactions between the chains. However, GP reduced the positive charge density
on chitosan chains permitting hydrophobic attraction and hydrogen bonding between
chitosan chains. Electrostatic attraction between the phosphate groups of the GP mole-
cule and the ammonium groups of chitosan contributed further to gelation. The rate and
manner of GP addition was found to be critical for formation of the desired gel. Addi-
tion of GP at a rapid rate or at higher temperature was found to result in chitosan pre-
cipitation. Rapid addition of GP into the chitosan solution resulted in a rapid increase in
pH without allowing for any of the above occurrences and hence resulted in chitosan
precipitation. The number of charged ammonium groups on the chitosan chain has been
reported to be an important parameter controlling gelation in this system (14, 15).
Thermoreversibility of chitosan/GP systems is attributed to reduced chitosan chain
polarity and increased hydrophobicity, increased interchain hydrophobic attraction and
thermally induced transfer of protons from chitosan amine groups to the phosphate
moiety of b-GP, leading to an attractive interchain interaction between chitosan chains.
Unlike hydrogen bonds, hydrophobic forces are known to be temperature dependent
and are suggested to be the source of thermoreversibility found in C-GP gels.
The in vitro release studies revealed that after an initial burst, 5-FU was released in a
sustained manner from the gels (Fig. 3) and only about 72 % of entrapped drug was re-
leased at the end of 12 h, indicating prolonged release of 5-FU. Also, at the end of 12 h,
the gel was found to remain intact within the release chamber. On exposure to release
medium, gels released as a burst about 40 % of entrapped drug during the first hour,
possibly due to surface 5-FU or due to the drug distributed in the tunnel of the gel dur-
ing the gelation process, which diffuses rapidly when the gel comes into contact with the
release medium. Following the initial burst, the 5-FU entrapped into the hydrogel was
released gradually over the 12 h period of measurement. Burst release in the case of
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Fig. 3. In vitro release of 5-FU
from C-GP-5FU gel.
5-FU could be beneficial in attaining high drug levels in the tumor immediately after ad-
ministration of the formulation. Gradual release that follows should serve to maintain
the drug level at the site of action for a prolonged period. Studies have shown that C-GP
systems can release the entrapped compound over a period of several hours to days de-
pending upon the molecular weight of chitosan used and also that the phenomena of
burst release of the entrapped compound is observed initially, followed by gradual re-
lease, irrespective of molecular mass of the entrapped drug. Pilocarpine entrapped in
C-GP containing systems for ocular delivery showed fast release of the entrapped drug
initially, after which the drug was released gradually over a period of 24 h. A similar
trend was observed for compounds like chlorpheniramine, calcein, etc. (9).
Acute toxicity studies: Determination of LD50
During the studies used for LD50 determination, masses of animals dosed at all lev-
els were found to decrease as the time proceeded (Table I). All three animals dosed at the
highest dose of 550 mg kg–1 died whereas those dosed at the lower level of 175 mg kg–1
survived. Based on these results, the LD50 of the test formulation was calculated to be
285 mg kg–1 as per the AOT425StatPgm. The LD50 of 5-FU on intraperitoneal administra-
tion to mice is reported to be 100 mg kg–1 (16). Thus, a 2.8-fold decrease in toxicity of the
test compound was observed.
The test drug in the present studies has a narrow therapeutic index (17). Following
intraperitoneal administration of 5-FU solution to human subjects, the drug concentra-
tion was four times greater in portal venous blood compared to that sampled from a pe-
ripheral artery or vein or from the hepatic vein (18). Furthermore, up to 70 % of the drug
was extracted by the liver during the first pass. Seven to 20 % of the parent drug was ex-
creted unchanged in the urine in 6 hours; over 90 % of this was excreted during the first
hour. The remaining percentage of the administered dose was metabolized, primarily in
the liver. The catabolic metabolism of fluorouracil resulted in degradation products (e.g.,
CO2, urea and a-fluoro-b-alanine), which were inactive (19).
In the present study, a decrease in toxicity in terms of reduced mortality and ab-
sence of any significant change in the mass of dosed animals was observed compared to
conventional injection. This decrease in toxicity can be attributed to a gradual and locali-
zed presentation of the cytotoxic agent from the formulation at the site of administra-
tion, which reduced systemic exposure and hence side effects. This is supported by ear-
lier findings during phase I clinical studies on intraperitoneal formulations of 5-FU,
which revealed that the concentration of the drug in the peritoneal cavity was 300 times
greater than that in the plasma (20).
In vitro cell line cytotoxicity studies
Cytotoxicity of the drug free C-GP systems was found to be concentration depend-
ent when evaluated in vitro in L-929 mouse fibroblast cells by an MTT assay. There was
no significant difference between the percent proliferation of controls and those of test
samples containing 10 to 50 mL of C-GP gels (p < 0.05), indicating the absence of cyto-
toxicity. But the test wells containing 100 mL of the C-GP system showed a significant
difference in percent proliferation of fibroblast cells in comparison with the control (p <
0.05) and exhibited toxic effects indicated by lower percent proliferation (60.57 %) (Fig. 4).
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Chitosan is recognized as a biocompatible polymer (21) with GRAS status. How-
ever, the C-GP system used in the present studies is relatively unexplored as regards its
toxicity. Since the system was intended to be used as an injectable depot, bioreactivity of
drug free gels was investigated on mammalian L-929 fibroblast cells with the help of an
MTT assay. L-929 mouse fibroblast cells have been used for evaluation of toxicity of
newly synthesized polymeric materials and for evaluation of biocompatibility of novel
drug delivery systems (22). Percent proliferation of fibroblast cells in contact with differ-
ent volumes of the chitoan-GP systems is indicative of cell viability.
In an earlier report, C-GP systems containing 1 % (m/V) chitosan and GP concentra-
tions ranging from 5–20 % (m/V) were prepared and cytotoxicity of the gels was moni-
tored using an extraction test by measuring the proliferation of goat bone marrow deri-
ved stem cells (gMSCs). Cytotoxicity of C-GP gels was found to increase with increasing
GP concentrations, but extraction fluids from C-GP with 10 % GP concentrations enhan-
ced the proliferation of gMSCs 4 to 11-fold compared to the negative control. It was also
found that chitosan with low GP concentrations (5–10 %, m/V) was not cytotoxic but en-
hanced the growth and proliferation of gMSCs (23).
The present study revealed a concentration dependent toxicity of the C-GP-system
for L-929 mouse fibroblast cells. While addition of lower amounts of C-GP systems to
the wells had no adverse effect on cell proliferation, the wells with higher amount (100
mL) of gel showed a statistically significant reduction in cell proliferation. This could be
attributed to the toxicity exerted by the system under evaluation at high concentrations,
and/or a two-fold dilution of DMEM in these wells, and/or the presence of rigid gels in
the wells when incubated at 37 °C, which could result in exertion of mechanical pressure
on the underlying cells. Nevertheless, the results indicate the need to exercise caution in
the in vivo use of these thermoreversibly gelling systems.
In vivo anti-tumor efficacy testing
All the control animals showed steady progression in the growth of the murine co-
lon tumor model colon-26. However, their body weights and survival were not adver-
sely affected by this growth and no morbidity and mortality were evident. A statistically
significant difference in the mass of animals and mortality was observed in the 5-FU and
C-GP-5-FU treated groups. At the dose administered, 5-FU solution injected intratumo-
rally demonstrated toxicity in terms of mass loss and mortality. However, no significant
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Fig. 4. Effect of addition of different
volumes of the C-GP system per
well on percent proliferation of L-929
mouse fibroblast cells 24 h after co-
-incubation.
mass loss was observed and no mortality was seen in the C-GP-5-FU gel treated mice up
to day 32 although the dose administered remained identical. Tumor volume measure-
ments indicate good efficacy when the results were analyzed using two-way ANOVA
Bonferroni’s multiple comparison test (p < 0.001). After a period of 17 days of treatment,
the increase in tumor volume of the control was significantly higher than that in both
treated groups (Figs. 5a and 5b). The tumor volume in control mice increased from 0.09
± 0.03 cm3 (n = 6) on day 1 of the study to 4.67 ± 0.84 cm3 on day 32. In contrast, tumor
volumes in the chitosan-GP-5FU treated mice, which were comparable on day 1 (0.087 ±
0.016), were measured as 0.87 ± 0.78 cm3 after 32 days. However, the given dose of 5-FU
as a commercial formulation was not tolerated by the 5-FU treated group, and animals,
although with regressed tumors, showed severe mortality beyond 10 days of treatment
and none of the animals survived beyond 17 days (Fig. 6a). In contrast, almost all the an-
imals treated with chitosan gel survived throughout the experimental period. Reduced
toxicity was also evident from the masses of animals (Fig. 6b). Whereas the animals trea-
ted with the 5-FU solution lost body mass soon after the treatment, no mass loss was ob-
served in animals treated with C-GP-5-FU during the experimental period. The relative
tumor volume was found to be lower for mice treated with both 5-FU solution and
C-GP-5-FU containing gel, since the tumor volume remained constant until the end of
the 5th injection. After 17 days, the tumor volume in treated groups was found to be in-
crease due to discontinuation of injections (Fig. 6c). The animals treated with 5-FU in so-
lution did not survive beyond 17 days.
Since 5-FU is widely used in colonic cancers, in the present study subcutaneously
grown murine colon tumors were used for evaluation of the developed formulation. Al-
though the proposed route of delivery is intraperitoneal, as a limitation of our experi-
ment, the colonic tumors could only be grown subcutaneously. Hence, injections were
administered intratumorally. Since injections were given intratumorally, localization of
the drug in the tumor would lead to reduced toxicity. To determine the therapeutic out-
come of formulations after intratumoral injection, the rate of tumor progression over ti-
me was measured following multiple injections of 5-FU in solution as well as C-GP-5FU.
Control mice showed rapid progression of tumor size and tumor volumes were signifi-
cantly higher than those of the animals receiving intratumoral injections of a cytotoxic
agent. High levels of mortality and morbidity seen in the group treated with 5-FU solu-
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Fig. 5. a) Tumor in untreated control BALB/c, b) tumor in C-GP-5-FU gels treated BALB/c at the
end of study.
a) b)
tion provided evidence that the drug redistributes from tumors to result in systemic tox-
icity. In contrast, animals belonging to the C-GP-5FU treated group remained relatively
free of morbidity and survived the entire test period. The relative tumor volume for both
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Fig. 6. a) Percent survival, b) body mass and c) relative tumor volume estimated in the control (u),
C-GP-5FU treated (n) and 5-FU treated BALB/c (p) (n = 6 per group). (Treated groups were admin-
istered a formulation equivalent to 60 mg kg–1 5-FU intratumorally, once every 3 days).
5-FU and C-GP-5FU treated mice remained close to one and any difference found was
statistically insignificant (p < 0.01), indicating comparable efficacy. In case of the 5-FU
solution treated mice, tumor volume was not measured beyond day 17 since animals did
not survive. After the 17th day of injection schedule, however, the relative tumor volume
gradually increased, i.e., tumor progression was noted. This was attributed to exhaus-
tion of the administered drug since no injections were given after day 17.
Lower morbidity and mortality associated with animals of the C-GP-5FU treated
group is a clear indicator of its lower systemic toxicity. The substantially lower systemic
exposure derived from gradual release of the drug into the tumor, followed by its uptake
into tumor cells, resulted in localization of the drug in the tumor site. The low but sus-
tained drug levels prevented tumor progression, but did not provide a sufficient driving
force for diffusion of the drug into systemic circulation. This could be the reason for re-
duced toxicity of the developed systems. Thus, comparable efficacy adjudged from tu-
mor volume measurements coupled with lower morbidity and mortality indicates that
the developed delivery system could be a promising agent for the treatment of cancers
of peritoneal organs.
Thermoreversible systems based on C-GP demonstrate a significant reduction in to-
xicity while retaining the efficacy of the cytotoxic drug 5-FU, as seen from the present
studies. The C-GP system investigated here needs further efficacy and toxicity evalua-
tion when administered intraperitoneally. Further, the system can be envisaged for use
in drug delivery via a number of routes, including parenteral (subcutaneous, intramus-
cular and intraperitoneal) and nasal, to achieve prolonged drug residence at these sites.
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